Nordson (NDSN) PT Raised to $287 at Baird

Baird analyst Michael Halloran raised the price target on Nordson (NASDAQ: NDSN) to $287.00 (from $272.00) while maintaining a Outperform rating.

The analyst comments "No change in outlook. F3Q results were ahead of expectations operationally driven by margins and ATS revenue. Guidance was held with largely unchanged F4Q organic assumptions, balancing F3Q outperformance and Atrion dilution. End market commentary suggests mixed revenue trends are likely to continue near-term with an improved ATS trajectory, offset by slices of MFS/IPS pressure (challenging comps broadly, softening interventional demand). That said, long-term opportunity is intact with a strong growth profile, best-in-class margin levels, and capital deployment optionality. Maintain Outperform rating."

You May Also Be Interested In

• Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
• Macy's (M) PT Raised to $25 at TD Cowen
• UnitedHealth Group (UNH) PT Lowered to $197 at TD Cowen